In today’s ACT Brief, we examine how large de-identified datasets are reshaping trial design and site strategy, why global ...
Linking de-identified datasets can power game-changing healthcare research and AI — but can also raise serious privacy risks if not handled with care. During ...
The Office of the National Coordinator will be examining the privacy and security risks of using de-identified patient health records in light of concerns that the records might be able to re-identify ...
Innovation in health care relies on the ability to figure out what the data is trying to teach us. Data analytics, including but not limited to GenAI powered data analytics, presents an insatiable ...
Each trading partner has data to identify the patient in their associated records, but that data has two important limitations: (1) the identifying data elements/fields and methods used by each ...
Bai is a professor of accounting and health policy at Johns Hopkins University. Hyman is the Scott K. Ginsburg professor of health law and policy at Georgetown University. In July, the Department of ...
Traditional clinical trial data are pseudonymized data, and these data may not contain information on a patient that directly identifies them, like a name, address, or phone number. However, ...
Handling sensitive patient data is a critical responsibility for organizations involved in clinical trials. To meet regulatory requirements, many rely on SDTM mapping—a process that converts raw ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results